Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Pharmaceutical firm Vertex Pharmaceuticals provided an undisclosed amount of equity funding for US-based immunotherapy developer Kymera Therapeutics on Wednesday as part of a $70m upfront payment made as part of a research and development agreement. Kymera had previously raised $95m across two rounds, from investors including corporate venturing units Lilly Ventures, Amgen Ventures, Pfizer Ventures,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.